RETA Reata Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RETA

Price (delayed)

$85.69

Market cap

$3.15B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.54

Enterprise value

$3.22B

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. ...

Highlights
Reata Pharmaceuticals's debt has decreased by 15% from the previous quarter and by 12% YoY
The company's equity has shrunk by 135% YoY
Reata Pharmaceuticals's revenue has plunged by 81% YoY and by 30% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.reatapharma.com
Peers: OVID

Key stats

What are the main financial stats of RETA
Market
Shares outstanding
36.73M
Market cap
$3.15B
Enterprise value
$3.22B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1,412.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,454.96
Earnings
Revenue
$2.22M
EBIT
-$278.03M
EBITDA
-$276.9M
Free cash flow
-$207.54M
Per share
EPS
-$8.54
Free cash flow per share
-$5.68
Book value per share
-$1.79
Revenue per share
$0.06
TBVPS
$14.09
Balance sheet
Total assets
$514.49M
Total liabilities
$580.19M
Debt
$119.46M
Equity
-$65.7M
Working capital
$338.81M
Liquidity
Debt to equity
-1.82
Current ratio
6.75
Quick ratio
6.57
Net debt/EBITDA
-0.28
Margins
EBITDA margin
-12,495.7%
Gross margin
100%
Net margin
-14,075%
Operating margin
-12,546.7%
Efficiency
Return on assets
-51.8%
Return on equity
-922.5%
Return on invested capital
-55.6%
Return on capital employed
-61%
Return on sales
-12,546.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RETA stock price

How has the Reata Pharmaceuticals stock price performed over time
Intraday
-2.57%
1 week
0.47%
1 month
92.52%
1 year
133.17%
YTD
125.56%
QTD
125.56%

Financial performance

How have Reata Pharmaceuticals's revenue and profit performed over time
Revenue
$2.22M
Gross profit
$2.22M
Operating income
-$278.03M
Net income
-$311.9M
Gross margin
100%
Net margin
-14,075%
Reata Pharmaceuticals's revenue has plunged by 81% YoY and by 30% from the previous quarter
Reata Pharmaceuticals's gross profit has shrunk by 81% YoY and by 30% QoQ
RETA's operating margin is down by 46% since the previous quarter
Reata Pharmaceuticals's net margin has decreased by 42% from the previous quarter

Growth

What is Reata Pharmaceuticals's growth rate over time

Valuation

What is Reata Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
1,412.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,454.96
Reata Pharmaceuticals's EPS has decreased by 4.3% YoY
The company's equity has shrunk by 135% YoY
Reata Pharmaceuticals's revenue has plunged by 81% YoY and by 30% from the previous quarter

Efficiency

How efficient is Reata Pharmaceuticals business performance
The ROE has shrunk by 186% QoQ
Reata Pharmaceuticals's ROS has decreased by 46% from the previous quarter
RETA's return on assets is down by 33% year-on-year and by 9% since the previous quarter
The company's return on invested capital rose by 13% QoQ

Dividends

What is RETA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RETA.

Financial health

How did Reata Pharmaceuticals financials performed over time
RETA's total assets is 11% less than its total liabilities
RETA's quick ratio is down by 40% YoY and by 24% QoQ
The current ratio has declined by 39% year-on-year and by 23% since the previous quarter
The company's equity has shrunk by 135% YoY
The debt to equity has plunged by 106% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.